Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept for Prevention of Abnormal Glucose Tolerance and Type 1 Diabetes in At‑Risk Relatives
2013-002249-13Phase 2Suspended
- Sponsor
- TrialNet Coordinating Center
- Start
- May 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) and impaired glucose tolerance (IGT) comparing Abatacept arm with Placebo arm (2 arms). Primary endpoint: Time to development of abnormal glucose tolerance or diabetes. Started May 2014; status: suspended.
02
Drugs
abatacept
03
Conditions
diabetes mellitus type 1 (T1D)impaired glucose tolerance (IGT)
Beyond the preview
Go deeper on 2013-002249-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002249-13.